Pirtobrutinib
JAYPIRCA
- Dosage form
- Tablet
- Available strengths
- 50 mg, 100 mg
- Drug class
- Bruton tyrosine kinase (BTK) inhibitor (non-covalent, targeted anticancer therapy)
- Common brand
- JAYPIRCA
Clinical overview. Pirtobrutinib (JAYPIRCA) is an oral, non-covalent Bruton tyrosine kinase (BTK) inhibitor used as monotherapy to treat adults with relapsed or refractory mantle cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma who have already received at least two prior lines of therapy including a BTK inhibitor. It is taken once daily and carries a serious warning for bleeding, along with risks of infections, low blood cell counts, second cancers, and heart rhythm problems, so treatment requires supervision by a clinician experienced with cancer therapies. It received market authorization with conditions in Canada, pending confirmatory trial results.
Indication
Common therapeutic uses
- Pirtobrutinib is used as a single agent to treat adults with mantle cell lymphoma that has relapsed or is refractory after at least two prior lines of therapy, including a BTK inhibitor.
- Pirtobrutinib is used as a single agent to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
- Pirtobrutinib was authorized in Canada under a Notice of Compliance with Conditions, based on promising early evidence, pending results of trials to confirm its clinical benefit.
Pregnancy
Risk assessment and monitoring considerations
- There are no adequate studies of pirtobrutinib in pregnant women, but animal studies show it can cause fetal harm, including reduced fetal weight, fetal death, and birth defects.
- Pirtobrutinib should not be used during pregnancy, and women of childbearing potential should have a pregnancy test before starting treatment.
- Women of childbearing potential should use highly effective contraception during treatment and for at least 5 weeks after the last dose; men with partners of childbearing potential should use effective contraception during treatment and for 3 months after the last dose.
Breastfeeding
Infant exposure considerations
- It is not known whether pirtobrutinib passes into human breast milk or affects milk production or the breastfed infant.
- Breastfeeding is not recommended during treatment and for one week after the last dose.
Geriatrics
Dosing and tolerability considerations
- No overall difference in effectiveness was seen between older and younger patients.
- Patients 65 years of age and older experienced higher rates of severe and serious side effects compared with younger patients, so closer monitoring is reasonable in this group.
Pediatrics
Use in children and adolescents
- Pirtobrutinib is not authorized for use in patients under 18 years of age, as no data are available to Health Canada for this population.
Dosage & Administration
Practical dosing and administration
- The recommended dose is 200 mg taken orally once daily, continued until the disease progresses or side effects become unacceptable.
- The tablet should be swallowed whole with water and not chewed, crushed, or split; it can be taken with or without food, at approximately the same time each day.
- Dose reductions are used to manage side effects: treatment is paused until recovery and then generally restarted at a lower dose, stepping down from 200 mg through 100 mg and 50 mg once daily depending on how many times a significant reaction has occurred, with permanent discontinuation after a fourth significant event.
- No dose adjustment is needed for mild or moderate kidney impairment, or for any degree of liver impairment.
- For severe kidney impairment, the dose should be reduced, typically to 100 mg once daily if the current dose is 200 mg, with close monitoring for toxicity; treatment should be stopped if the dose is already at 50 mg once daily.
- If a dose is missed by more than 12 hours, skip it and take the next dose at the regular scheduled time; do not take an extra dose.
- If vomiting occurs after a dose, do not take a replacement dose; continue with the next scheduled dose.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- The product monograph does not describe a specific treatment for pirtobrutinib overdose; management consists of general supportive measures.
Common side effects
Frequently reported tolerability concerns
- Fatigue may occur.
- Musculoskeletal pain (muscle, bone, or joint pain) may occur.
- Diarrhea may occur.
- Bruising may occur.
- Cough may occur.
- Nausea may occur.
- Constipation may occur.
- Swelling (edema) may occur.
- Dizziness may occur.
- Rash may occur.
- Headache may occur.
- Decreased appetite may occur.
- Fever may occur.
- Insomnia may occur.
- Shortness of breath (dyspnea) may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Serious, and sometimes fatal, bleeding has occurred, including gastrointestinal and intracranial bleeding; the risk is higher in patients taking blood thinners or antiplatelet drugs.
- Low blood cell counts, including neutropenia, anemia, and thrombocytopenia, can become severe and require blood count monitoring.
- Serious and sometimes fatal infections, including bacterial, viral, and fungal infections, and opportunistic infections such as Pneumocystis jirovecii pneumonia, can occur.
- Second primary cancers, most often non-melanoma skin cancers, have developed in some patients; regular skin checks and sun protection are recommended.
- Heart rhythm disturbances, including atrial fibrillation, atrial flutter, and other arrhythmias, may occur; report palpitations, dizziness, fainting, or shortness of breath promptly.
- Liver injury, including rare cases of liver failure, has been reported with this class of drug.
- Tumor lysis syndrome, a rapid breakdown of cancer cells that can affect kidney function and electrolyte balance, has been reported rarely, mainly in patients with a high burden of disease before starting treatment.
- Seek urgent medical attention for unusual bleeding or bruising, black or bloody stools, sudden severe headache, chest pain, a fast or irregular heartbeat, fainting, signs of infection such as fever or chills, or yellowing of the skin or eyes.
Use with caution
Situations requiring closer assessment
- Use with caution, and monitor blood counts regularly, given the risk of low neutrophil, red blood cell, and platelet counts.
- Use with caution in patients taking anticoagulant or antiplatelet medications, given the increased risk of bleeding; discuss the risks and benefits of continuing these medications with a specialist.
- Consider stopping pirtobrutinib for 3 to 5 days before and after surgery, depending on the type of surgery and bleeding risk.
- Use with caution in patients with cardiac risk factors, such as high blood pressure or a prior history of arrhythmia, given the risk of atrial fibrillation and other rhythm disturbances.
- Use with caution in patients at risk of tumor lysis syndrome, such as those with a high burden of disease before starting treatment.
- Consider preventive measures, including vaccination and antimicrobial prophylaxis, in patients at increased risk of opportunistic infections.
- Monitor liver function before starting treatment and periodically during treatment.
- Monitor for the appearance of new skin lesions or growths, given the risk of second skin cancers.
- Treatment should be initiated and supervised only by a qualified healthcare practitioner experienced in the use of anticancer therapies.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to pirtobrutinib or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
Clinically relevant combinations
- Strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir, and clarithromycin, increase pirtobrutinib blood levels and may require a lower pirtobrutinib dose.
- Strong CYP3A inducers, such as rifampin and rifabutin, and moderate CYP3A inducers, such as efavirenz and bosentan, reduce pirtobrutinib blood levels and may require a higher pirtobrutinib dose.
- St. John's Wort, a strong inducer of CYP3A, should be avoided with pirtobrutinib.
- Pirtobrutinib can raise blood levels of sensitive CYP3A substrates such as midazolam, everolimus, sirolimus, and tacrolimus, increasing their effects and side effects.
- Pirtobrutinib can raise blood levels of sensitive CYP2C8 substrates such as repaglinide.
- Pirtobrutinib can raise blood levels of sensitive CYP2C19 substrates such as omeprazole.
- Pirtobrutinib can raise blood levels of P-glycoprotein substrates such as digoxin.
- Pirtobrutinib can raise blood levels of BCRP substrates such as rosuvastatin.
- Use with warfarin or other vitamin K antagonists has not been studied; weigh the risks and benefits of combining pirtobrutinib with any anticoagulant or antiplatelet therapy.
Food interactions
Meal-related administration
- Pirtobrutinib can be taken with or without food; a high-fat meal modestly lowers and delays peak blood levels but does not meaningfully change total drug exposure.
Time of administration
Practical scheduling
- Take at approximately the same time each day, with or without food.
Storage
Product handling
- Store at room temperature (15°C to 30°C).
Patient take-away
Key counselling points for a quick closing summary
- Pirtobrutinib (JAYPIRCA) is a once-daily targeted cancer therapy for certain relapsed or hard-to-treat lymphomas and leukemias that have already been treated with a BTK inhibitor.
- It carries a risk of serious bleeding, low blood cell counts, infections, and heart rhythm changes, so regular blood tests and monitoring by your cancer care team are essential.
- Tell your care team about all medications you take, including over-the-counter products and herbal supplements, since many can change pirtobrutinib levels or its effect on other drugs.
- Seek urgent care for unusual bleeding, signs of infection, a fast or irregular heartbeat, or yellowing of the skin or eyes.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.